Value through Innovation01 August 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice

- Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries


Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments

- For Ex-US and Ex-UK Media Only

Winners of the 2014 European PRRS Research Award announced


Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis


- For media outside UK, US and Canada

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund


Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

- For Ex-US and Ex-UK Media Only

Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

- For Ex-US and Ex-UK Media Only

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung

- For media outside UK and US only

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

- For Ex-US and Ex-UK Media Only

Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

- For Non-U.S. and Non-UK Media

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

- For Non-U.S. and Non-U.K. Media

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting

- For Non-US and Non-UK Media

Nintedanib* slowed disease progression in IPF independent of patients’ lung function impairment at baseline

- For media outside UK, US and Canada

European Respiratory Society International Congress 2014
TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD

- For media outside the US, the UK and Canada

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care


- For Media outside the US, the UK & Canada only

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin

- Non-US/Non-UK/Non-Canadian Media

Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention

- For Non-US/Non-UK/Non-Canadian Media